Aprogen Biologics Amends CB Issuance Terms
에이프로젠바이오로직스
003060
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2755
Risk-adjusted indicator based on 2755 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Initial Conversion Price: 2,353 KRW/Share
- • Minimum Adjustment Price: 1,648 KRW/Share
- • First Put Option Date: January 1, 2028
- • First Put Option Rate: 103.0760%
AI Analysis Summary
Aprogen Biologics Inc. has amended its Material Fact Report regarding the issuance of convertible bonds. The initial conversion price is confirmed at 2,353 KRW per share, with a minimum adjustment price of 1,648 KRW. The amendment clarifies the finalization of these prices and details the put option terms for bondholders, with the first exercise date on January 1, 2028, at a rate of 103.0760%. This update provides clarity on the CB terms but does not introduce new financial figures that would significantly alter the initial dilution impact.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.